The phase 3 trials showed not only success in the lowering of glucose, but also the reduction in weight
Furthermore, its tolerability profile, which includes weight gain, edema/fluid retention, fractures, and (rarely) bladder cancer in long-term use, could hinder its potential repositioning for depression [173]
Obesity-associated inflammation and aging can accelerate NAD turnover through PARP-1 and CD38 pathways [85, 106, 116]
Back The Economist (24 Oct 2024) 'GLP-1s like Ozempic are among the most important drug breakthroughs ever'
The following are used to make these patches: Note: The actual GLP-1 agonist drug patches containing semaglutide are still under trial are known to reduce appetite, manage cravings and hunger, and give a feeling of fullness 4
Hlscher C (2022) Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimers and Parkinsons diseases